Servier said Tuesday that sevasemten, an experimental treatment for Becker muscular dystrophy, failed to slow the disease in the Phase 3 GRAND CANYON study. The long, placebo-controlled trial marks a setback for the drug and for patients with the rare condition, for which no treatments are currently approved.
Servier acquired the drug in June from its original developer, Edgewise Therapeutics, for $1.55 billion in cash, with about $1 billion more possible through milestone payments. Sevasemten had previously shown promising results in a smaller randomized study.
The company said the Phase 3 findings did not align with some results from earlier clinical studies. Servier is analyzing the trial data alongside relevant prior clinical data to better understand the results.
Sources: STAT News.